Post-prenylation-processing enzymes as new targets in oncogenesis

Nature Reviews Cancer

Volumn 5, Issue 5, 2005, Pages 405-412

  Winter Vann, Ann M ^a   Casey, Patrick J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; N ACETYL S FARNESYLCYSTEINE; N ACETYL S GERANYLGERANYLCYSTEINE; ONCOPROTEIN; PROTEIN CDC42; PROTEIN HRAS; PROTEIN ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE; PROTEIN KRAS; PROTEIN NRAS; PROTEIN PTP4A3; PROTEIN RCE1 PROTEASE; PROTEIN RHOC; PROTEINASE; PROTEINASE INHIBITOR; RAC PROTEIN; RAS PROTEIN; RHEB PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

CANCER CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; METHYLATION; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEINASE INHIBITION; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL PROLIFERATION; ENDOPEPTIDASES; HUMANS; NEOPLASMS; PROTEIN ISOPRENYLATION; PROTEIN METHYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RAS PROTEINS;

EID: 18344394166     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1612     Document Type: Review

References (113)

1. Glomset, J. A. & Farnsworth, C. C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu. Rev. Cell Biol. 10, 181-205 (1994).
2. Zhang, F. L. & Casey, P. J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269 (1996).
3. Casey, P. J. & Seabra, M. C. Protein prenyltransferases. J. Biol. Chem. 271, 5289-5292 (1996).
4. Ashby, M. N. CaaX converting enzymes. Curr. Opin. Lipidol. 9, 99-102 (1998).
5. Young, S. G., Ambroziack, P., Kim, E. & Clarke, S. in The Enzymes 3rd edn Vol. 21 (eds Tamanoi, F. and Sigman, D. G.) 156-213 (Academic, San Diego, 2001).
6. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Rss. 49, 4682-4689 (1989).
7. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nature Rev. Cancer 3, 459-465 (2003).
8. Hahn, W. C. et al. Creation of human tumour cells with defined genetic elements. Nature 400, 464-468 (1999).
9. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
10. Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Rev. Cancer 4, 361-370 (2004).
11. Jaffe, A. B. & Hall, A. Rho GTPases in transformation and metastasis. Adv. Cancer Res. 84, 57-80 (2002).
12. Sahai, E. & Marshall, C. J. RHO-GTPases and cancer. Nature Rev. Cancer 2, 133-142 (2002).
13. Ishida, D. et al. Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 4, 55-65 (2003).
14. Daaka, Y. G proteins in cancer: the prostate cancer paradigm. Sci. STKE 216, re2 (2004).
15. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
16. Schwindinger, W. F. & Robishaw, J. D. Heterotrimeric G-protein βγ-dimers in growth and differentiation. Oncogene 20, 1653-1660 (2001).
17. Heasley, L. E. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20, 1563-1569 (2001).
18. 12 to the serum response element and to cellular transformation. Proc. Natl Acad. Sci. USA 94, 10098-10103 (1997).
19. Cates, C. A. et al. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett. 110, 49-55 (1996).
20. Collins, S. P., Reoma, J. L., Gamm, D. M. & Uhler, M. D. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem. J. 345, 673-580 (2000).
21. Hutchison, C. J. Lamins: building blocks or regulators of gene expression? Nature Rev. Mol. Cell Biol. 3, 848-858 (2002).
22. Ashar, H. R. et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. 275, 30451-30457 (2000).
23. Kloog, Y. & Cox, A. D. Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. Semin. Cancer Biol. 14, 253-261 (2004).
24. Kato, K. et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl Acad. Sci. USA 89, 6403-6407 (1992).
25. Hori, Y. et al. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene 6, 515-522 (1991).
26. Allal, C. et al. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J. Biol. Chem. 275, 31001-31008 (2000).
27. Fukada, Y. et al. Farnesylated γ-subunit of photoreceptor G protein indispensable for GTP-binding. Nature 346, 658-660 (1990).
28. Gibbs, J. B., Oliff, A. & Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77, 175-178 (1994).
29. Mazieres, J., Pradines, A. & Favre, G. Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett. 206, 159-167 (2004).
30. Kohl, N. E. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1, 792-797 (1995).
31. Doll, R. J., Kirschmeier, P. & Bishop, W. R. Farnesyltransferase inhibitors as anticancer agents: critical crossroads. Curr. Opin. Drug Discov. Devel. 7, 478-486 (2004).
32. Gotlib, J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr. Hematol. Rep. 4, 77-84 (2005).
33. Cox, A. D. & Der, C. J. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2, 388-393 (2002).
34. James, G. L., Goldstein, J. L. & Brown, M. S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270, 6221-6226 (1995).
35. Whyte, D. B. et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464 (1997).
36. Sebti, S. M. & Der, C. J. Searching for the elusive targets of farnesyltransferase inhibitors. Nature Rev. Cancer 3, 945-951 (2003).
37. Kim, E. et al. Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J. Biol. Chem. 274, 8383-8390 (1999).
38. Bergo, M. O. et al. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J. Biol. Chem. 275, 17605-17610 (2000).
39. Clarke, S. & Tamanoi, F. Fighting cancer by disrupting C-terminal methylation of signaling proteins. J. Clin. Invest. 113, 513-515 (2004).
40. Boyartchuk, V. L., Ashby, M. N. & Rine, J. Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 275, 1796-1800 (1997).
41. Otto, J. C., Kim, E., Young, S. G. & Casey, P. J. Cloning and characterization of a mammalian prenyl protein-specific protease. J. Biol. Chem. 274, 8379-8382 (1999).
42. Schmidt, W. K., Tam, A., Fujimura-Kamada, K. & Michaelis, S. Endoplasmic reticulum membrane localization of Rce1 p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. Proc. Natl Acad. Sci. USA 95, 11175-11180 (1998).
43. Jang, G. F. & Gelb, M. H. Substrate specificity of mammalian prenyl protein-specific endoprotease activity. Biochemistry 37, 4473-4481 (1998).
44. Chen, Y., Ma, Y. T. & Rando, R. R. Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease. Biochemistry 35, 3227-3237 (1996).
45. Pei, J. & Grishin, N. V. Type II CAAX prenyl endopeptidases belong to a novel superfamily of putative membrane-bound metalloproteases. Trends Biochem. Sci. 26, 275-277 (2001).
46. Trueblood, C. E. et al. The CaaX proteases, Afcip and Rce1p, have overlapping but distinct substrate specificities. Mol. Cell. Biol. 20, 4381-4392 (2000).
47. Bergo, M. O. et al. On the physiological importance of endoproteolysis of CAAX proteins: heart-specific RCE1 knockout mice develop a lethal cardiomyopathy. J. Biol. Chem. 279, 4729-4736 (2004).
48. Dai, Q. et al. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J. Biol. Chem. 273, 15030-15034 (1998).
49. Romano, J. D., Schmidt, W. K. & Michaelis, S. The Saccharomyces cerevisiae prenylcysteine carboxyl methyltransferase Ste14p is in the endoplasmic reticulum membrane. Mol. Biol. Cell 9, 2231-2247 (1998).
50. Marr, R. S., Blair, L. C. & Thorner, J. Saccharomyces cerevisiae STE14 gene is required for COOH-terminal methylation of a-factor mating pheromone. J. Biol. Chem. 265, 20057-20060 (1990).
51. Hrycyna, C. A., Sapperstein, S. K., Clarke, S. & Michaelis, S. The Saccharomyces cerevisiae STE14 gene encodes a methyltransferase that mediates C-terminal methylation of a-factor and RAS proteins. EMBO J. 10, 1699-1709 (1991).
52. Kagan, R. M. & Clarke, S. Widespread occurrence of three sequence motifs in diverse S-adenosylmethionine-dependent methyltransferases suggests a common structure for these enzymes. Arch. Biochem. Biophys. 310, 417-427 (1994).
53. Tan, E. W., Perez-Sala, D., Canada, F. J. & Rando, R. R. Identifying the recognition unit for G protein methylation. J. Biol. Chem. 266, 10719-10722 (1991).
54. Lin, X. et al. Prenylcysteine carboxylmethyltransferase is essential for the earliest stages of liver development in mice. Gastroenterology 123, 345-351 (2002).
55. Bergo, M. O. et al. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J. Biol. Chem. 276, 5841-5845 (2001).
56. Smeland, T. E., Seabra, M. C., Goldstein, J. L. & Brown, M. S. Geranylgeranylated Rab proteins terminating in Cys-Ala-Cys, but not Cys-Cys, are carboxyl-methylated by bovine brain membranes in vitro. Proc. Natl Acad. Sci. USA 91, 10712-10716 (1994).
57. Takai, Y., Sasaki, T. & Matozaki, T. Small GTP-binding proteins. Physiol. Rev. 81, 153-208 (2001).
58. Silvius, J. R. & l'Heureux, F. Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers. Biochemistry 33, 3014-3022 (1994).
59. Chen, Z., Otto, J. C., Bergo, M. O., Young, S. G. & Casey, P. J. The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules. J. Biol. Chem. 275, 41251-41257 (2000).
60. Michaelson, D., Ahearn, I., Bergo, M., Young, S. & Philips, M. Membrane trafficking of heterotrimeric G proteins via the endoplasmic reticulum and Golgi. Mol. Biol. Cell 13, 3294-3302 (2002).
61. Michaelson, D. et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol. Biol. Cell (in the press).
62. Hrycyna, C. A. & Clarke, S. Farnesyl cysteine C-terminal methyltransferase activity is dependent upon the STE14 gene product in Saccharomyces cerevisiae. Mol. Cell. Biol. 10, 5071-5076 (1990).
63. Sapperstein, S., Berkower, C. & Michaelis, S. Nucleotide sequence of the yeast STE14 gene, which encodes farnesylcysteine carboxyl methyltransferase, and demonstration of its essential role in a-factor export. Mol. Cell. Biol. 14, 1438-1449 (1994).
64. Parish, C. A., Smrcka, A. V. & Rando, R. R. Functional significance of βγ subunit carboxymethylation for the activation of phospholipase C and phosphoinositide 3-kinase. Biochemistry 34, 7722-7727 (1995).
65. Fukada, Y. et al. Effects of carboxyl methylation of photoreceptor G protein γ subunit in visual transduction. J. Biol. Chem. 269, 5163-5170 (1994).
66. Maske, C. P. et al. A carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease Rce1 and carboxymethylation. J. Cell Biol. 162, 1223-1232 (2003).
67. Backlund, P. S. Jr. Post-translational processing of RhoA. Carboxyl methylation of the carboxyl-terminal prenylcysteine increases the half-life of RhoA. J. Biol Chem. 272, 33175-33180 (1997).
68. Bergo, M. O. et al. Inactivation of lcmt inhibits transformation by oncogenic K-Ras and B-Raf. J. Clin. Invest. 113, 539-550 (2004).
69. Philips, M. R. et al. Carboxyl methylation of Ras-related proteins during signal transduction in neutrophils. Science 259, 977-980 (1993).
70. Perez, E., West, A. H., Stock, A. M. & Djordjevic, S. Discrimination between different methylation states of chemotaxis receptor Tar by receptor methyltransferase CheR. Biochemistry 43, 953-961 (2004).
71. Kort, E. N., Goy, M. F., Larsen, S. H. & Adler, J. Methylation of a membrane protein involved in bacterial chemotaxis. Proc. Natl Acad. Sci. USA 72, 3939-3943 (1975).
72. Choi, Y. J. et al. Assays of human postprenylation processing enzymes. Methods Enzymol. 332, 103-114 (2001).
73. Tan, E. W. & Rando, R. R. Identification of an isoprenylated cysteine methyl ester hydrolase activity in bovine rod outer segment membranes. Biochemistry 31, 5572-5578 (1992).
74. Dunten, R. L., Wait, S. J. & Backlund, P. S. Jr. Fractionation and characterization of protein C-terminal prenyl-cysteine methylesterase activities from rabbit brain. Biochem. Biophys. Res. Commun. 208, 174-182 (1995).
75. Bergo, M. O. et al. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol. Cell. Biol. 22, 171-181 (2002).
76. Alyagari, A. L., Taylor, B. R., Aurora, V., Young, S. G. & Shannon, K. M. Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood 101, 2250-2252 (2003).
77. Schlitzer, M., Winter-Vann, A. & Casey, P. J. Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1. Bioorg. Med. Chem. Lett. 11, 425-427 (2001).
78. Ma, Y. T., Gilbert, B. A. & Rando, R. R. Inhibitors of the isoprenylated protein endoprotease. Biochemistry 32, 2386-2393 (1993).
79. Chen, Y. Selective inhibition of Ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease. Ann. NY Acad. Sci. 886, 103-108 (1999).
80. Shi, Y. Q. & Rando, R. R. Kinetic mechanism of isoprenylated protein methyltransferase. J. Biol. Chem. 267, 9547-9551 (1992).
81. Winter-Vann, A. M. et al. Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate. Proc. Natl Acad. Sci. USA 100, 6529-6534 (2003).
82. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J. Biol. Chem. 272, 25380-25385 (1997).
83. Kramer, K. et al. Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis. Mol. Biol. Cell 14, 848-857 (2003).
84. Lu, Q. et al. Isoprenylcysteine carboxyl methyltransferase modulates endothelial monolayer permeability. Involvement of RhoA carboxyl methylation. Circ. Res. 94, 306-315 (2004).
85. Hoffman, D. R., Cornatzer, W. E. & Duerre, J. A. Relationship between tissue levels of S-adenosylmethionine, S-adenylhomocysteine, and transmethylation reactions. Can. J. Biochem. 57, 56-65 (1979).
86. Chiang, P. K. et al. S-adenosylmethionine and methylation. FASEB J. 10, 471-480 (1996).
87. Perez-Sala, D., Gilbert, B. A., Tan, E. W. & Rando, R. R. Prenylated protein methyltransferases do not distinguish between farnesylated and geranylgeranylated substrates. Biochem. J. 284, 835-840 (1992).
88. Kowluru, A. et al. Glucose- and GTP-dependent stimulation of the carboxyl methylation of CDC42 in rodent and human pancreatic islets and pure β cells. Evidence for an essential role of GTP-binding proteins in nutrient-induced insulin secretion. J. Clin. Invest. 98, 540-555 (1996).
89. Chiu, V. K. et al. Carboxyl methylation of ras regulates membrane targeting and effector engagment. J. Biol. Chem. 279, 7346-7352 (2003).
90. Roullet, J. B. et al. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J. Clin. Invest. 97, 2384-2390 (1996).
91. Scheer, A. & Gierschik, P. Farnesylcysteine analogues inhibit chemotactic peptide receptor-mediated G-protein activation in human HL-60 granulocyte membranes. FEBS Lett. 319, 110-114 (1993).
92. Ma, Y. T. et al. Mechanistic studies on human platelet isoprenylated protein methyltransferase: farnesylcysteine analogs block platelet aggregation without inhibiting the methyltransferase. Biochemistry 33, 5414-5420 (1994).
93. Ding, J. et al. Farnesyl-L-cysteine analogs can inhibit or initiate superoxide release by human neutrophils. J. Biol. Chem. 269, 16837-16844 (1994).
94. Philips, M. R. Methotrexate and Ras methylation: a new trick for an old drug? Sci. STKE 225, pe13 (2004).
95. Chen, Y. Inhibition of K-ras-transformed rodent and human cancer cell growth via induction of apoptosis by irreversible inhibitors of Ras endoprotease. Cancer Lett. 131, 191-200 (1998).
96. Backlund, P. S. Post-translational processing of RhoA. Carboxyl methylation of the carboxyl-terminal prenylcysteine increases the half-life of Rhoa. J. Biol. Chem. 272, 33175-33180 (1997).
97. Garnett, M. J. & Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319 (2004).
98. Rowinsky, E. K. Signal events: cell signal transduction and its inhibition in cancer. Oncologist 8 (Suppl. 3), 5-17 (2003).
99. Reid, T. S., Terry, K. L., Casey, P. J. & Beese, L. S. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol. 343, 417-433 (2004).
100. McFariane, S. I., Munyappa, R., Francisco, R. & Sowers, J. R. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J. Clin. Endocrinol. Metab. 87, 1451-1458 (2002).
101. Auer, J., Berent, R., Weber, T. & Eber, B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr. Med. Chem. 9, 1831-1850 (2002).
102. Chan, K. K., Oza, A. M. & Siu, L. L. The statins as anticancer agents. Clin. Cancer Res. 9, 10-19 (2003).
103. Soltis, D. A. et al. Expression, purification, and characterization of the human squalene synthase: use of yeast and baculoviral systems. Arch. Biochem. Biophys. 316, 713-723 (1995).
104. Sagami, H., Morita, Y. & Ogura, K. Purification and properties of geranylgeranyl-diphosphate synthase from bovine brain. J. Biol. Chem. 269, 20561-20566 (1994).
105. Furfine, E. S., Leban, J. J., Landavazo, A., Moomaw, J. F. & Casey, P. J. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 34, 6857-6862 (1995).
106. Kusama, T. et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 61, 4885-4891 (2001).
107. Thorpe, J. L., Doitsidou, M., Ho, S. Y., Raz, E. & Farber, S. A. Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation. Dev. Cell 6, 295-302 (2004).
108. Ye, J. et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl Acad. Sci. USA 100, 15865-15870 (2003).
109. Chiu, V. K. et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biol. 4, 343-350 (2002).
110. Michaelson, D. et al. Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J. Cell Biol. 152, 111-126 (2001).
111. rho proteins. J. Cell Biol. 119, 617-627 (1992).
112. Kwiatkowski, D. J. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol. Ther. 2, 471-476 (2003).
113. Bardelli, A. et al. PRL-3 expression in metastatic cancers. Clin. Cancer Res. 9, 5607-5615 (2003).